Access Bio, Inc. Logo

Access Bio, Inc.

Develops and manufactures in vitro diagnostic solutions for infectious diseases.

950130 | KO

Overview

Corporate Details

ISIN(s):
KR8840090003
LEI:
Country:
United States of America
Address:
65 Clyde Road Suite A, Somerset NJ

Description

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-08-18 00:00
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내 )
Korean 3.0 KB
2025-08-14 00:00
[기재정정]사업보고서 (2024.12)
Korean 2.8 MB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 3.1 MB
2025-08-14 00:00
반기또는분기매출액미달사실발생
Korean 6.0 KB
2025-08-14 00:00
기타시장안내 (상장적격성 실질심사 관련)
Korean 3.2 KB
2025-08-14 00:00
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean 4.6 KB
2025-05-20 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 26.3 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-07 00:00
주식등의대량보유상황보고서(일반)
Korean 88.3 KB
2025-03-26 00:00
정기주주총회결과
Korean 28.5 KB
2025-03-26 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.6 KB
2025-03-18 00:00
감사보고서제출
Korean 26.7 KB
2025-03-18 00:00
사업보고서 (2024.12)
Korean 2.8 MB
2025-03-11 00:00
주주총회소집결의
Korean 15.7 KB

Automate Your Workflow. Get a real-time feed of all Access Bio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Access Bio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Access Bio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.